Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 275

1.

Improving the management of patients with prostate cancer receiving long-term androgen deprivation therapy.

Schulman C, Irani J, Aapro M.

BJU Int. 2012 Jun;109 Suppl 6:13-21. doi: 10.1111/j.1464-410X.2012.11216.x. Review.

PMID:
22672121
[PubMed - indexed for MEDLINE]
2.

Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature.

Abrahamsson PA.

Eur Urol. 2010 Jan;57(1):49-59. doi: 10.1016/j.eururo.2009.07.049. Epub 2009 Aug 7. Review.

PMID:
19683858
[PubMed - indexed for MEDLINE]
3.

Androgen deprivation therapy: evidence-based management of side effects.

Ahmadi H, Daneshmand S.

BJU Int. 2013 Apr;111(4):543-8. doi: 10.1111/j.1464-410X.2012.11774.x. Epub 2013 Jan 25. Review.

PMID:
23351025
[PubMed - indexed for MEDLINE]
4.

Intermittent androgen deprivation in prostate cancer patients: factors predictive of prolonged time off therapy.

Strum SB, Scholz MC, McDermed JE.

Oncologist. 2000;5(1):45-52.

PMID:
10706649
[PubMed - indexed for MEDLINE]
Free Article
5.

[Osteoporosis in men receiving androgen deprivation therapy for non-metastatic prostate cancer].

Kudlacek S, Puntus T.

Wien Med Wochenschr. 2012 Sep;162(17-18):380-5. doi: 10.1007/s10354-012-0106-z. Epub 2012 Aug 9. Review. German.

PMID:
22875632
[PubMed - indexed for MEDLINE]
6.

Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy.

Grossmann M, Hamilton EJ, Gilfillan C, Bolton D, Joon DL, Zajac JD.

Med J Aust. 2011 Mar 21;194(6):301-6. Review.

PMID:
21426285
[PubMed - indexed for MEDLINE]
7.

Management of decreased bone mineral density in men starting androgen-deprivation therapy for prostate cancer.

Panju AH, Breunis H, Cheung AM, Leach M, Fleshner N, Warde P, Duff-Canning S, Krahn M, Naglie G, Tannock I, Tomlinson G, Alibhai SM.

BJU Int. 2009 Mar;103(6):753-7. doi: 10.1111/j.1464-410X.2008.08156.x. Epub 2008 Oct 24.

PMID:
19007370
[PubMed - indexed for MEDLINE]
8.
9.

Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials.

Sciarra A, Abrahamsson PA, Brausi M, Galsky M, Mottet N, Sartor O, Tammela TL, Calais da Silva F.

Eur Urol. 2013 Nov;64(5):722-30. doi: 10.1016/j.eururo.2013.04.020. Epub 2013 Apr 19. Review.

PMID:
23628492
[PubMed - indexed for MEDLINE]
10.

Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer.

Kiratli BJ, Srinivas S, Perkash I, Terris MK.

Urology. 2001 Jan;57(1):127-32.

PMID:
11164157
[PubMed - indexed for MEDLINE]
11.

Background to and management of treatment-related bone loss in prostate cancer.

Berruti A, Tucci M, Terrone C, Gorzegno G, Scarpa RM, Angeli A, Dogliotti L.

Drugs Aging. 2002;19(12):899-910. Review.

PMID:
12495366
[PubMed - indexed for MEDLINE]
12.

Androgen deprivation therapy: past, present and future.

Schröder F, Crawford ED, Axcrona K, Payne H, Keane TE.

BJU Int. 2012 Jun;109 Suppl 6:1-12. doi: 10.1111/j.1464-410X.2012.11215.x. Review.

PMID:
22672120
[PubMed - indexed for MEDLINE]
13.

Advanced prostate cancer treated with intermittent or continuous androgen deprivation in the randomised FinnProstate Study VII: quality of life and adverse effects.

Salonen AJ, Taari K, Ala-Opas M, Viitanen J, Lundstedt S, Tammela TL; FinnProstate Group.

Eur Urol. 2013 Jan;63(1):111-20. doi: 10.1016/j.eururo.2012.07.040. Epub 2012 Jul 27.

PMID:
22857983
[PubMed - indexed for MEDLINE]
14.

Long-term effects of androgen deprivation therapy in prostate cancer patients.

Basaria S, Lieb J 2nd, Tang AM, DeWeese T, Carducci M, Eisenberger M, Dobs AS.

Clin Endocrinol (Oxf). 2002 Jun;56(6):779-86.

PMID:
12072048
[PubMed - indexed for MEDLINE]
15.

Intermittent hormonal therapy in the treatment of metastatic prostate cancer: a randomized trial.

Mottet N, Van Damme J, Loulidi S, Russel C, Leitenberger A, Wolff JM; TAP22 Investigators Group.

BJU Int. 2012 Nov;110(9):1262-9. doi: 10.1111/j.1464-410X.2012.11120.x. Epub 2012 Apr 13.

PMID:
22502816
[PubMed - indexed for MEDLINE]
16.

Continuous vs. intermittent androgen deprivation therapy for metastatic prostate cancer.

Langenhuijsen JF, Badhauser D, Schaaf B, Kiemeney LA, Witjes JA, Mulders PF.

Urol Oncol. 2013 Jul;31(5):549-56. doi: 10.1016/j.urolonc.2011.03.008. Epub 2011 May 10.

PMID:
21561791
[PubMed - indexed for MEDLINE]
17.

A randomized phase II trial evaluating different schedules of zoledronic acid on bone mineral density in patients with prostate cancer beginning androgen deprivation therapy.

Lang JM, Wallace M, Becker JT, Eickhoff JC, Buehring B, Binkley N, Staab MJ, Wilding G, Liu G, Malkovsky M, McNeel DG.

Clin Genitourin Cancer. 2013 Dec;11(4):407-15. doi: 10.1016/j.clgc.2013.04.029. Epub 2013 Jul 5.

PMID:
23835291
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Preventing bone loss during androgen deprivation therapy for prostate cancer: early experience with neridronate.

Magno C, Anastasi G, Morabito N, Gaudio A, Maisano D, Franchina F, Galì A, Frisina N, Melloni D.

Eur Urol. 2005 May;47(5):575-80; discussion 580-1.

PMID:
15826746
[PubMed - indexed for MEDLINE]
19.

Zoledronic acid to prevent bone loss in Chinese men receiving androgen deprivation therapy for prostate cancer.

Yee CH, Ng CF, Wong AY, Chan CK, Hou SM, Yip SK.

Asia Pac J Clin Oncol. 2011 Jun;7(2):168-73. doi: 10.1111/j.1743-7563.2011.01388.x.

PMID:
21585697
[PubMed - indexed for MEDLINE]
20.

Osteoporosis during androgen deprivation therapy for prostate cancer.

Smith MR.

Urology. 2002 Sep;60(3 Suppl 1):79-85; discussion 86. Review.

PMID:
12231056
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk